Roche declares final overall survival outcomes from breast cancer treatment trial

Roche has reported final overall survival results from the Phase III APHINITY trial, which evaluated Perjeta (pertuzumab) with Herceptin (trastuzumab) and chemotherapy in 4,804 patients with HER2-positive early-stage breast cancer. The Perjeta-based regimen demonstrated a 17% reduction in mortality risk compared to Herceptin and chemotherapy alone, with 91.6% of patients still alive at ten years versus 89.8% in the control group. Among patients with lymph node-positive disease, the regimen reduced mortality risk by 21%. No new safety concerns were identified, and cardiac safety remained consistent with earlier findings. The trial confirmed long-term invasive disease-free survival benefits, with a hazard ratio of 0.79. However, no survival benefit was observed in node-negative patients. Roche emphasized the importance of early treatment and reaffirmed the regimen's role as a standard of care. Perjeta is currently approved in over 120 countries for both early-stage and metastatic HER2-positive breast cancer treatment.

19-05-2025